SCHEDULE 13G/A: JPMorgan Chase & Co. Discloses 0.2% Beneficial Ownership in Keros Therapeutics, Inc.
Beneficial Ownership Report
JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a 0.2% beneficial ownership stake in Keros Therapeutics, Inc. as of April 30, 2025.
Summary
- JPMorgan Chase & Co. filed an Amendment No. 1 to Schedule 13G regarding its beneficial ownership in KEROS THERAPEUTICS, INC.
- The filing indicates that JPMorgan Chase & Co. beneficially owns 113,803 shares of Keros Therapeutics, Inc. Common Stock.
- This aggregate amount represents 0.2% of the class of securities.
- JPMorgan Chase & Co. holds sole voting power and sole dispositive power over all 113,803 shares.
- No shared voting or dispositive power is reported.
- The filing was made by JPMorgan Chase & Co. as a parent holding company or control person.
- Relevant subsidiaries identified include J.P. Morgan Securities LLC, JPMorgan Chase Bank, National Association, and J.P. Morgan Markets Limited.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership, providing neutral information without indicating positive or negative sentiment regarding the company's performance or outlook.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a minor passive investment by a major financial institution, JPMorgan Chase & Co., in a biotechnology company, Keros Therapeutics, Inc. Such filings are routine disclosures of beneficial ownership and do not typically signal strategic shifts or significant investment intent beyond passive holding, especially at a 0.2% stake. It reflects a standard portfolio holding within the financial services sector's investment activities.
Stakeholder Impact
- Shareholders: Provides transparency regarding institutional ownership, confirming a minor passive stake by JPMorgan Chase & Co.
Key Dates
| Date | Description |
|---|---|
| 04/30/2025 | Date of event which requires filing of this statement |
| 05/05/2025 | Date of signature for the Schedule 13G filing |
Keywords
JPMorgan Chase & Co., Keros Therapeutics Inc., Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Investment Holding, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.